search icon

    Market Snapshot

    • S&P Futures

      4,132.75

    • Dow Futures

      32,794

    • Nasdaq Futures

      13,103.75

    blog search icon

    Ambrx Biopharma Inc.

    (NYSE:AMAM)

    $2.38

    $0.01

    0.42%

    Ambrx Biopharma Inc. Chart

    AMAM Stock Price Today

    Ambrx Biopharma Inc. (AMAM) stock rallied over 0.42% intraday to trade at $2.38 a share on NYSE. The stock opened with a gain of 1.28% at $2.35 and touched an intraday high of $2.48, rising 0.42% against the last close of $2.37. The stock went to a low of $2.38 during the session.

    Stock Snapshot

    $2.37

    Prev. Close

    91.08 Million

    Market Cap

    $2.38

    Day Low

    $2.35

    Open

    42.22 Million

    Number of Shares

    $2.48

    Day High

    -

    P/E ratio

    -1.75

    EPS (TTM)

    4.41

    Cash Flow per Share

    0.05

    Free Float in %

    5.52

    Book Value

    13,837

    Volume

    Ambrx Biopharma Inc. Historical Data

    DateOpenHighLowCloseVolume
    2022-08-08$2.35$2.48$2.38$2.3813,837
    2022-08-05$2.35$2.47$2.35$2.3712,100
    2022-08-04$2.43$2.547$2.35$2.3521,600
    2022-08-03$2.55$2.57$2.42$2.4213,300
    2022-08-02$2.6$2.62$2.33$2.3326,700
    2022-08-01$2.75$2.75$2.62$2.6411,500
    2022-07-29$2.78$2.91$2.78$2.788,000
    2022-07-28$2.71$2.78$2.71$2.753,300
    2022-07-27$2.93$2.93$2.782$2.83,700
    2022-07-26$2.91$2.91$2.815$2.8153,100

    Contact Details

    10975 North Torrey Pines Road
    La Jolla, CA 92037
    United States

    Webiste:AMAM

    858 875 2400

    Company Information

    Employees-

    Beta-

    Sales or Revenue7.46 Million

    5Y Sales Change-

    Fiscal Year Ends2021-12-30

    SectorHealth Care

    IndustryBiotechnology

    About Company

    Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.

    Frequently Asked Questions

    icon

    What is the current Ambrx Biopharma Inc. (AMAM) stock price?

    Ambrx Biopharma Inc. (NYSE: AMAM) stock price is $2.38 as of the last check on Monday, August 8. During the trading session, AMAM stock reached the peak price of $2.48 while $2.38 was the lowest point it dropped to.

    icon

    AMAM's industry and sector of operation?

    The NYSE listed AMAM is part of Biotechnology industry that operates in the broader Health Care sector. Ambrx Biopharma Inc. , a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform.

    icon

    Who are the executives of AMAM?

    Dr. Feng Tian Ph.D.
    Pres, Member of Scientific Advisory Board, CEO & Chairman
    Ms. Sonja Nelson CPA
    Chief Financial Officer
    Dr. Shawn Shao-Hui Zhang Ph.D.
    Exec. VP of R&D Operations and GM of Ambrx China
    Dr. Janice Lu M.D., Ph.D.
    Chief Medical Officer

    icon

    What is the AMAM stock price today?

    AMAM stock traded closed the last session at $2.38, which is $0.009999999999999787 or 0.42194092827003316% lower than its previous close of $2.37. AMAM's current trading price is 2.15% lower than its 52-week high of $19.5 where as its distance from 52-week low of 2.33% is -87.79%.

    icon

    How many employees does AMAM have?

    Number of AMAM employees currently stands at -. AMAM operates from 10975 North Torrey Pines Road, La Jolla, CA 92037, United States.

    icon

    Link for AMAM official website?

    Official Webiste of $AMAM is: https://ambrx.com

    icon

    How do I contact AMAM?

    AMAM could be contacted at AMAM operates from 10975 North Torrey Pines Road, La Jolla, CA 92037, United States, or at phone #858 875 2400 and can also be accessed through its website.

    icon

    How many shares of AMAM are traded daily?

    AMAM stock volume for the day was 13,837 shares while in the previous session number of AMAM shares traded was 13,837 . The average number of AMAM shares traded daily for last 3 months was 9.88 Thousands.

    icon

    How much did AMAM change today?

    The percentage change in AMAM stock occurred in the recent session was 0.42194092827003316% while the dollar amount for the price change in AMAM stock was $0.009999999999999787.

    icon

    What price range AMAM stock been trading in?

    In the recent session, the day high for AMAM stock was $2.48 while the low for AMAM stock touched on the day was $2.38.

    icon

    What is the market cap of AMAM currently?

    The market value of AMAM currently stands at 91.08 Million with its latest stock price at $2.38 and 42.22 Million of its shares outstanding.